Skip to main content
Clinical Trials/NCT00425464
NCT00425464TerminatedPhase 3

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Synchrony Dual Optic Intraocular Lens in Patients Undergoing Cataract Extraction

Abbott Medical Optics39 sites in 1 country410 target enrollmentStarted: November 2005Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Terminated
Enrollment
410
Locations
39
Primary Endpoint
Distance corrected near visual acuity

Study Overview

Brief Summary

The purpose of the study is to determine if the Synchrony Dual Optic Accommodating Intraocular Lens can be used safely and effectively in post cataract extraction subjects

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients must be scheduled to undergo primary intraocular lens implantation for the correction of aphakia following extraction of a senile cataract.
  • Patients must have a cataract causing reduction in visual acuity to a level of 20/40 or worse with BAT on medium setting.
  • Patients must require Synchrony® Lens correction of 16D - 28D or, if participating in the control study, patients must require a Clariflex® (AMO®), Phacoflex® II models SI30NB (AMO®) or a SI40NB (AMO®).
  • Patients must have ≤ 1.0 D of preoperative keratometric astigmatism.
  • Patients must have clear intraocular media other than cataract(s).
  • Patients must be age 50 or older at the time of implantation.
  • Patient must be willing and able to return for all scheduled follow-up examinations and have signed a written informed consent form.

Exclusion Criteria

  • Patients with any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.).
  • Patients with glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP > 22 mmHg.
  • Patients with previous retinal detachment or retinal pathology including age- related macular degeneration.
  • Patients with diabetes, currently being treated systemically.
  • Patients with systemic or ocular disease that may prevent the patient from achieving uncorrected distance visual acuity of 20/32 or better post operatively.
  • Patients with congenital bilateral cataract.
  • Patients who require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents. The use of tamsulosin hydrochloride (Flomax®) is also excluded preoperatively due to floppy iris syndrome.
  • Patients with best corrected visual acuity of 20/80 or worse in the fellow eye not attributable to cataract.
  • Patients who are currently participating or have participated in an investigational study, other than this study, within the past 60 days.
  • Patients who have had previous ocular surgery in the operative eye, including refractive surgery.

Outcomes

Primary Outcomes

Distance corrected near visual acuity

Time Frame: 1 Mo, 4-6 Mo, 12 Mo, 24 Mo, & 36 Mo

Secondary Outcomes

  • Best corrected distance visual acuity(1 Mo, 4-6 Mo, 12 Mo, 24 Mo, & 36 Mo)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (39)

Loading locations...

Similar Trials

A Prospective Multicenter Clinical Study... | Clinical Trial